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Abstract 
Background: In vivo depletion of host T cells with antithymocyte globulin (ATG) is a common strategy for prevent‑
ing graft‑versus‑host disease in allogeneic hematopoietic stem cell transplantation (HSCT). The total dose of ATG in 
conditioning regimens appears to be an important factor that influences the outcome in recipients of transplants. 
However, the optimal ATG dosage has not been established to date. It remains unclear whether, in the setting of hap‑
loidentical HSCT (haploHSCT), different doses of ATG might exert differential influences on the recovery of lympho‑
cyte subpopulations.
Methods: This retrospective study analyzed lymphocyte recovery and its correlation to viral infection in two groups 
of patients that received different doses of ATG before haploHSCT. We performed flowcytometry to determine immu‑
nophenotypes of CD19+ B cells and CD3+, CD4+, CD8+, CD4+CD45RA+, CD4+CD45RO+, CD4+CD28+, CD8+CD28+, 
and CD4−CD8− T cells.
Results: We found that, compared to 6 mg/kg, 10 mg/kg ATG significantly hampered the recoveries of CD4+, 
CD4+CD45RA+, and CD4+CD45RO+ T cells in the first 2 months following haploHSCT. Similarly, compared to 6 mg/kg, 
the 10 mg/kg dose of ATG negatively influenced the recoveries of CD4−CD8− and CD8+CD28+ T cells; recovery was 
delayed for 6 and 12 months after transplantation, respectively. Moreover, we showed that an increase in Epstein‑Barr 
virus (EBV) infections, associated with the higher dose of ATG, was correlated with the delayed recovery of CD4−CD8− 
double negative T cells.
Conclusions: The present study revealed a differential impact of different ATG conditioning doses on the recoveries 
of T cell subpopulations post‑haploHSCT. This study was the first to connect the recovery of CD4−CD8− T cells to the 
risk of EBV infection after HSCT. These findings will facilitate optimization of the ATG conditioning dosage and improve 
the outcome of patients with leukemia that receive haploHSCT.
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Background
Haploidentical hematopoietic stem cell transplantation 
(haploHSCT) constitutes an important alternative for 
patients with leukemia that lack a donor with matching 
human leukocyte antigen (HLA). However, graft-ver-
sus-host disease (GVHD) is a frequent, life-threatening 
complication of haploHSCT. To prevent GVHD, patients 
often receive antithymocyte globulin (ATG), a polyclonal 
immunoglobulin preparation obtained by immunizing 
rabbits or horses with human thymocytes or T cell lines. 
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been quite successful in preventing the development of 
both acute and chronic GVHD after hematopoietic stem 
cell transplantation (HSCT) from HLA-matched, unre-
lated donors [1–3]. Studies from our group and others 
have suggested that ATG can also overcome the negative 
influence of HLA-mismatched HSCT [4–7].
However, the virtual depletion of T cells increases both 
the risk of developing a severe infection and the risk of a 
malignancy relapse after HSCT. Therefore, it has become 
critical to determine a suitable dose of ATG in condition-
ing regimens [8]. Although the total dose of ATG appears 
to have an important influence on the overall clinical out-
come of transplantation, studies on the impact of differ-
ent ATG doses have produced inconsistence [9–11], and 
an optimal dose has not been established.
It has been recognized that viral infections and other 
complications of HSCT are closely associated with the 
reconstitution of the immune system. A growing num-
ber of studies have demonstrated the negative impact 
of ATG on the recovery of lymphocytes after transplan-
tation [12–14]. In the haploHSCT setting, our previous 
prospective study reported that, compared to 6  mg/kg 
ATG, 10 mg/kg ATG conditioning regimen increased the 
risk of EBV infection, but reduced the incidence of grades 
III–IV acute GVHD [15]. Although patients that received 
higher ATG dose showed delayed recoveries of CD19+ B 
cells, CD3+ T cells, and CD4+ T cells 30 days after trans-
plantation, it was not clear whether lymphocyte recov-
ery at later stages and the recoveries of differential T cell 
subpopulations were affected by different doses of ATG. 
Moreover, the cause-consequence relationship between 
immunodeficiency and the occurrence of viral infections 
was not demonstrated in this context.
In the present study, we extended the comparison 
between the two different ATG-conditioning doses in the 
context of haploHSCT to include more lymphocyte sub-
populations and longer follow-up times. Thus, in addition 
to CD19+ B cells and CD3+ and CD4+ T cells, we studied 
recoveries of CD8+, CD4+CD45RA+, CD4+CD45RO+, 
CD4+CD28+, CD8+CD28+, and CD4−CD8− T cells for 
an extended time course (12  months after transplanta-
tion). Our results showed hampered recovery of some T 
cell subsets and a correlation between the delayed recov-
ery and increased risk of EBV infection with 10  mg/kg 
ATG treatment. These results emphasized the need to 
optimize the ATG dosage in conditioning regimens to 
facilitate recovery of the immune system and improve the 
outcome for recipients of haploHSCT.
Methods
Patients and study design
The aim of this study was to compare lymphocyte recov-
ery and its correlation to viral infections between patients 
that received two different doses of ATG as conditioning 
for haploHSCT. We retrospectively screened participants 
from an open-label, prospective, randomized trial (No. 
ChiCTR-TRC-11001761), which included 224 patients 
randomly assigned to receive either 6 mg/kg or 10 mg/kg 
ATG [15]. All subjects were diagnosed with standard-risk 
hematological malignancies and underwent haploHSCT 
in our institute from December 2010 to May 2012. The 
Ethics Committee of Peking University Institute of 
Hematology approved the study protocol. All recipients 
and their donors signed consent forms. Because immune 
reconstitution was neither the primary nor the secondary 
end point in that prospective study, only 60 subjects had 
been monitored for lymphocyte recovery at serial time 
points (30, 60, 90, 180, and 360  days post-transplanta-
tion). Therefore, these 60 subjects were recruited for the 
current study.
Patients were conditioned with intensive chemother-
apy-based regimens (mainly busulfan, cyclophospha-
mide, and ATG), as described in detail previously [15]. 
ATG (thymoglobulin; rabbit ATG, Imtix Sangstat, Lyon, 
France) doses were administered from day −5 to day 
−2 before transplantation. Patients that received 6  mg/
kg ATG (ATG-6 group) were administrated 1.5  mg/kg 
per day; patients that received 10  mg/kg ATG (ATG-
10 group) were administrated 2.5  mg/kg per day. The 
transplant procedures, GVHD prophylaxis (includ-
ing cyclosporine A and short-term methotrexate with 
mycophenolate mofetil) and treatment, and evaluations 
of acute GVHD and viral infections/reactivations were 
described previously [15].
Immunophenotyping analysis
Immunophenotyping for B and T lymphocytes was per-
formed with flowcytometry post-haploHSCT. Briefly, 
fresh peripheral blood cells were stained with fluoro-
chrome-labeled monoclonal antibodies against cluster of 
differentiation (CD) cell surface molecules, CD19, CD3, 
CD4, CD8, CD45RO, CD45RA, and CD28 (Beckton 
Dickinson, San Jose, CA, USA). Polychromatic flow cyto-
metric analyses were performed with a custom 7-laser 
high resolution LSRII cell analyzer (Beckton Dickinson).
Statistical analysis
Statistical differences between groups in age, incidences 
of acute GVHD and viral infections, and recoveries of 
lymphocyte subpopulations at different time points were 
analyzed with the Mann–Whitney U test. Statistical dif-
ferences between the two groups in gender and type of 
primary disease were analyzed with the Chi squared test. 
Bivariate correlations between the recoveries of T cell 
subpopulations and the incidence of EBV infection were 
analyzed with the Spearman test. Statistical significance 
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was defined as P ≤0.05, based on a two-tailed test. All 
calculations were carried out with SPSS 16.0 statistical 
software (SPSS Inc, Chicago, IL, USA).
Results
Characteristics of patients
The characteristics of patients in the two different ATG 
groups are summarized in Table 1. Previous studies sug-
gested that the age of recipients and the numbers of 
CD34+ cells in grafts could influence immune recovery. 
In the present study, there were no statistical differences 
in age or the numbers of CD34+ cells in grafts between 
groups. Moreover, the gender ratio and types of primary 
disease were similar between the ATG-6 and ATG-10 
groups (Table 1). In addition, all included subjects under-
went the same procedures of donor priming (recom-
binant human granulocyte-colony stimulating factor), 
graft harvesting (peripheral blood progenitor cells and 
unmanipulated bone marrow), and GVHD prophy-
laxis (cyclosporine A and short-term methotrexate with 
mycophenolate mofetil).
Recoveries of T lymphocyte subpopulations were delayed 
with 10 mg/kg ATG
We first analyzed the peripheral white blood cell (WBC) 
and the absolute lymphocyte counts determined in rou-
tine blood tests from day 30 to 360 after haploHSCT. 
As shown in Table  2, the median levels of total WBC 
and lymphocyte counts were not significantly different 
between the two ATG groups at the indicated time points 
post-transplantation. This finding indicated that the 
recoveries of peripheral WBCs and lymphocytes were not 
affected by the dose of ATG in the conditioning regimen.
Next, we compared the recoveries of B and T lym-
phocytes between the ATG-6 and ATG-10 groups at 
serial time points and within 1  year after haploHSCT. 
We determined the absolute numbers of nine lympho-
cyte subpopulations with immunophenotyping, namely: 
CD19+ B cells, and CD3+, CD4+, CD8+, CD4+CD45RA+, 
CD4+CD45RO+, CD4+CD28+, CD8+CD28+, and 
CD4−CD8− T cells (Table 3). On day 30 after HSCT, the 
median counts of nearly all lymphocyte subsets, except 
CD8+ T cells, were significantly lower in the ATG-10 
group than in the ATG-6 group. That is, the difference 
between groups were statistically significant (P  ≤  0.05) 
in comparing median counts of CD4+, CD4+CD45RA+, 
CD4+CD45RO+, CD4+CD28+, CD8+CD28+, and 
CD4−CD8− T cells by the end of the first month post-
transplantation; however, differences in the numbers of 
CD19+ B cells and CD3+ T cells were only close to the 
significance (P  =  0.07, Table  3). These results demon-
strated that 10  mg/kg of ATG administration, in con-
trast to 6 mg/kg of ATG treatment, was associated with 
a delayed recovery of lymphocyte subpopulations as early 
as the first month following haploHSCT.
The median levels of CD4+, CD4+CD45RA+ and 
CD4+CD45RO+ T cells (representing naive and 
Table 1 Clinical characteristic of patients
ATG antithymocyte globulin, AML acute myeloid leukemia, ALL acute 
lymphoblastic leukemia, BM bone marrow, BU busulfan, CML chronic myeloid 
leukemia, CSA cyclosporine A, CY cyclophosphamide, HSCT hematopoietic stem 
cell transplantation, MDS myelodysplastic syndrome, MMF mycophenolate 
mofetil, MTX methotrexate, PB peripheral blood
ATG-6 ATG-10 P value
Subjects, n 29 31
Age, years, median (range) 22 (16–48) 29 (15–48) 0.11
Gender, n (%)
 Male 18 (62.1) 24 (77.4) 0.19
 Female 11 (37.9) 7 (22.6)
Diagnosis, n (%)
 AML 12 (41.4) 14 (45.2) 0.77
 ALL 12 (41.4) 12 (38.7)
 CML 2 (6.9) 3 (9.6)
MDS (RAEB) 3 (10.3) 2 (6.5)
CD34+ cells in graft,  
×106/kg, median (range)
2.4 (0.7–4.9) 3.1 (0.3–7.8) 0.32
Donor type Related donors
HLA typing 1–3/6 Mismatch
Stem cell source BM + PB
Conditioning regimen BU + CY + ATG
GVHD prophylaxis CSA + MMF + MTX
Table 2 Peripheral white blood cells (WBC) and  lympho-
cyte counts after ATG-conditioned haploHSCT, 109/L
The recoveries of peripheral WBC and lymphocytes are indicated by the median 
(minimum, maximum) absolute cell counts
Group WBC Lymphocyte
Day 30 ATG‑6 5.9 (1.6–15.7) 0.3 (0.1–2.7)
ATG‑10 4.7 (2.0–18.1) 0.3 (0.1–2.3)
p value 0.95 0.47
Day 60 ATG‑6 4.9 (1.9–14.9) 1.1 (0.3–3.3)
ATG‑10 4.3 (0.1–26.1) 0.9 (0.0–10.8)
p value 0.46 0.57
Day 90 ATG‑6 4.5 (1.7–11.2) 1.6 (0.2–3.2)
ATG‑10 3.8 (1.0–9.5) 1.2 (0.2–6.2)
p value 0.27 0.34
Day 180 ATG‑6 5.2 (2.8–8.7) 2.0 (0.9–3.9)
ATG‑10 4.9 (0.5–7.2) 1.8 (0.2–4.8)
p value 0.54 0.36
Day 360 ATG‑6 5.8 (3.8–15.0) 2.4 (0.4–5.2)
ATG‑10 5.4 (2.0–9.6) 2.2 (0.9–4.7)
p value 0.58 0.88
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memory CD4+ T cells) in the ATG-10 group continu-
ously declined over 60  days compared to levels in the 
ATG-6 group. After that, from 90 to 360 days after trans-
plantation, the median counts of these three T-cell sub-
sets were comparable between the two groups (Table 3). 
This finding suggested that the recoveries of total, naive, 
and memory CD4+ T cells were hamperAs presented 
ined by the higher dose of ATG in the early stage, but not 
the late stage, post-haploHSCT.
In contrast, the median counts of CD8+CD28+ T cells 
(representing normal cytotoxic T lymphocytes) were 
apparently lower at all time points in the ATG-10 group 
than in the ATG-6 group. The P value for comparisons at 
30, 60, 90, and 360 days were always ≤0.05; nevertheless 
P value rose to 0.06 at 180 days (Table 3). This observa-
tion implied that the recovery of active CD8+ T cells was 
slowed by a higher dose of ATG for relatively long times, 
and this in turn, might have contributed to the outcomes 
of haploHSCT observed in this group.
Notably, the recovery of a special T-cell subpopulation 
defined as CD4−CD8− T cells was also hampered in the 
ATG-10 group at 30, 60, 90, and 180  days, with P val-
ues  <0.05 compared to the ATG-6 group. However, the 
median counts of CD4−CD8− T cells were comparable 
between the two groups at 360  days after haploHSCT 
(Table 3). It was recognized that CD4−CD8− T cells rep-
resent a small subpopulation of the normal immune sys-
tem. Therefore, the impact of impairing the recovery of 
this double-negative T-cell subset during the first half 
year after ATG-conditioned haploHSCT requires further 
investigation.
High dose ATG conditioning was associated with a lower 
incidence of acute GVHD but increased EBV reactivation 
after haploHSCT
Next, we evaluated whether different doses of ATG 
administration pre-transplantation might impact the 
incidence of acute GVHD (aGVHD). As shown in 
Table 4, the total incidence of aGVHD was significantly 
decreased in the ATG-10 group compared to the ATG-6 
group (45.2 vs 72.4 %, P = 0.03), but there was no differ-
ence in the occurrence of significant and severe aGVHD 
(grades II–IV) between groups. The onset time of 
aGVHD was comparable between groups.
It was previously shown that a higher risk of viral infec-
tions was associated with the use of ATG. In the cur-
rent study, the risk of cytomegalovirus (CMV) infection 
was similar in the ATG-10 and ATG-6 groups. However, 
Epstein–Barr virus (EBV) reactivation occurred more 
frequently in ATG-10 group than in the ATG-6 group 
(32.2 vs 6.9  %, P =  0.02). The onset times of CMV and 
EBV reactivations were not statistically different between 
the two ATG-dose groups (Table 4).
Recovery of CD4−CD8− T cells was negatively correlated 
with EBV reactivation after 10 mg/kg ATG conditioning
Given the observation that a higher ATG condition-
ing dose influenced both the recovery of T lymphocyte 
subpopulations and the incidence of EBV reactivation 
in the current study, we were interested in determining 
whether these two phenotypes were correlated. Accord-
ingly, we performed a Bivariate Correlations analysis 
between the median counts of T cell subpopulations that 
showed significantly delayed recoveries in the ATG-10 
group (Table  3) and the incidence of EBV reactivation 
in that group. Among five T lymphocyte subsets (CD4+, 
CD4+CD45RA+, CD4+CD45RO+, CD8+CD28+, and 
CD4−CD8− T cells), only the recovery of CD4−CD8− T 
cells on day 30 was significantly correlated to the occur-
rence of EBV reactivation (Spearman’s rp  =  −0.378, 
P = 0.036, Table 5). The correlation between the recovery 
of CD4−CD8− T cells on day 90 and EBV infection nearly 
reached statistical significance (Spearman’s rp = −0.352, 
P = 0.066, Table 5). We note that median onset time of 
EBV reactivation was 51 days (range 22–102 days) after 
transplantation in the ATG-10 group (Table 4). Based on 
this observation, we speculated that, among patients that 
received a higher dose of ATG, the delayed recovery of 
CD4−CD8− T cells in the first month increased the risk 
of EBV infection. In turn, an EBV infection might slow 
down the recovery of CD4−CD8− T cells at later stages 
pos-haploHSCT.
Next, we performed a correlation analysis between the 
recoveries of T cell subpopulations and the incidence 
of EBV reactivation for all subjects, irrespective of the 
ATG dose. As presented in Table  6, the recoveries of 
CD4−CD8− T cells on day 30 (Spearman’s rp  =  -0.313, 
P  =  0.015) and day 90 (Spearman’s rp  =  −0.318, 
P = 0.019) were significantly correlated to the occurrence 
Table 4 Incidences of acute GVHD and CMV/EBV infections 
after ATG-conditioned haploHSCT
ATG-6 ATG-10 p value
Acute GVHD, n (%)
 Total 21 (72.4) 14 (45.2) 0.03
 Grade II–IV 11 (37.9) 8 (25.8) 0.32
 Grade III–IV 4 (13.8) 2 (6.5) 0.35
Median day of onset grade II‑IV 
aGVHD (range)
29 (10–42) 30 (9–80) 0.32
CMV reactivation, n (%) 22 (75.9) 24 (77.4) 0.89
Median day of onset CMV reactiva‑
tion (range)
36 (22–77) 37.5 (22–102) 0.73
EBV reactivation, n (%) 2 (6.9) 10 (32.2) 0.02
Median day of onset EBV reactiva‑
tion (range)
60.5 (47–74) 51 (22–102) 0.61
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of EBV reactivation. Taken together, our data suggested 
that CD4−CD8− T cells could be an important subpopu-
lation that plays a role in response to EBV infection after 
haploHSCT.
Discussion
T-cell depletion with ATG is a common strategy for 
preventing GVHD in allogeneic HSCT settings. How-
ever, the potentially negative impact of ATG has been 
an issue of debate [16–18]. In the setting of haploHSCT, 
few studies have demonstrated the influence of ATG dos-
age modulation on lymphocyte recovery and its asso-
ciation with the risk of viral infections. Consistent with 
our previous work [15], we showed that high-dose ATG 
was associated with delayed recoveries of CD19+ B cells, 
CD3+ T cells, and CD4+ T cells during the first month 
after haploHSCT. Here, we also showed that high-dose 
ATG delayed the recoveries of CD4+, CD4+CD45RA+, 
and CD4+CD45RO+ T cells for 2  months, delayed the 
recovery of CD4−CD8− T cells for 6 months, and delayed 
the recovery of CD8+CD28+ T cells for 12 months after 
transplantation. Moreover, our bivariate correlation anal-
ysis indicated that the persistent delay in CD4−CD8− T 
cell recovery was closely related to an increased risk of 
EBV infection post-haploHSCT.
Double negative, CD4−CD8− T cells are defined by 
exclusion; they comprise the group of CD3+ T cells that 
do not express CD4 or CD8, and they are infrequently 
observed in peripheral blood and lymphoid organs [19]. 
Traditionally, studies on double-negative T cells have 
predominantly focused on the negative effects involved 
in autoimmune syndromes and inflammation [20, 21]. A 
recent review proposed potential roles of double-nega-
tive T cells in the normal immune system [22]. Although 
functional analyses of double-negative T cells lagged 
behind analyses of well-known T cell subpopulations, 
normal double-negative T cells have emerged as potent 
effector cells involved in host defense [23]. A previous 
study demonstrated that double-negative T cells com-
prised a major host-response T cell subset in the lungs of 
mice during inhalational Francisella infections [24]. In the 
context of HSCT, the characteristics of double-negative 
T-cell recovery have not been documented. The present 
study was the first to report that high-dose ATG condi-
tioning significantly delayed the recovery of CD4−CD8− 
T cells after haploHSCT, and this delay was correlated 
with an increased risk of EBV reactivation. These novel 
findings suggested that CD4−CD8− T cells are important 
in protecting against viral infections; however, we could 
not rule out the contributions of other functional T cell 
subpopulations. In addition, CD4−CD8− T cells com-
prise a mixed subset which includes cells that express 
either αβ or γδ T cell receptors and, other cells that are 
incompletely characterized [19]. It would be interesting 
to identify which subset of CD4−CD8− T cells functions 
in protecting against EBV reactivation after HSCT.
Apart from EBV and CMV, other viruses, like adeno-
virus (AdV), BK virus (BKV), and human herpes virus 6 
(HHV6), can potentially cause severe infections after allo-
geneic HSCT [25–27]. These three viruses were recently 
added into the list of viruses that require monitoring in 
routine examinations for recipients of haploHSCT in our 
institute. The question of whether the incidences of AdV, 
BKV, and HHV6 reactivation are affected by different 
conditioning doses of ATG awaits future investigations.
We previously reported that administration of 10 mg/
kg ATG resulted in a significant decrease in the occur-
rence of severe aGVHD compared to a 6  mg/kg ATG 
dose [15]. In the current study, the incidences of grades 
III-IV aGVHD were not statistically different between 
the groups, although the ratios of incidences in the ATG-
10 versus ATG-6 group were 6.5  % (2/31) and 13.8  % 
(4/29; Table 4). The failure to observe a difference could 
be attributed to the limited size of the present retrospec-
tive study.
Both the dosage and timing of ATG administration 
have been suggested as critical factors in T-lymphocyte 
recovery after HSCT [9]. The present study showed that 
6  mg/kg ATG was related to a faster recovery of T cell 
subsets and lower incidence of EBV infection after hap-
loHSCT, compared to 10  mg/kg AGT. Our previous 
study showed a significant reduction in the occurrence of 
severe aGVHD with 10  mg/kg ATG treatment. Because 
the overall survival rates were comparable between the 
ATG-6 and ATG-10 groups [15], we currently use 10 mg/
kg ATG to reduce the occurrence of aGVHD. Further 
investigation is required to determine whether an inter-
mediate ATG dose might preserve the protective effect of 
preventing GVHD without delaying T-cell recovery. We 
recently initiated a multi-center clinical trial to compare 
the outcomes of recipients of haploHSCT that received 
10 versus 7.5  mg/kg ATG. We hope the results of that 
trial will facilitate optimization of the ATG conditioning 
dose. On the other hand, it has been shown that condi-
tioning with ATG closer to the day of transplantation and 
longer active ATG exposure were correlated with slower 
T-cell recovery after HSCT [28, 29]. In the present study, 
blood concentrations of active ATG after haploHSCT 
were not monitored. However, evaluation of the time of 
lymphocyte exposure to ATG and its impact on T-cell 
reconstitution may also facilitate optimization of the con-
ditioning dosage and timing pre-haploHSCT.
Conclusions
The present study demonstrated that 10  mg/kg ATG, 
compared to 6  mg/kg ATG, significantly hampered 
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the recoveries of some T-cell subpopulations in a time-
dependent manner, post-haploHSCT. Our study was the 
first to connect the recovery of CD4−CD8− T cells to the 
risk of EBV infection after HSCT. Future prospective and 
large cohort studies should provide more unbiased evi-
dences to clarify our findings and benefit the overall out-
come in recipients of haploHSCT.
Authors’ contributions
JL collected and analyzed the data, and wrote the manuscript. LPX, ZB, YJC, 
YW, and XHZ collected and interpreted the data; XJH designed the study 
and critically revised the manuscript. All authors read and approved the final 
manuscript.
Acknowledgments
This study is supported by Key Program of the National Natural Science Foun‑
dation of China (Grant no. 81230013) and National Natural Science Foundation 
of China (Grant no. 81370666).
Competing interests
The authors declare that they have no competing interests.
Received: 6 August 2015   Accepted: 4 December 2015
References
 1. Theurich S, Fischmann H, Chakupurakal G, Shimabukuro‑Vornhagen 
A, Chemnitz JM, Holtick U, Rothe A, Scheid C, Hallek M, Skoetz N, von 
Bergwelt‑Baildon M. Anti‑thymocyte globulins for post‑transplant graft‑
versus‑host disease prophylaxis‑A systematic review and meta‑analysis. 
Crit Rev Oncol Hematol. 2013;88:178–86.
 2. Devillier R, Furst S, El‑Cheikh J, Castagna L, Harbi S, Granata A, Crocchiolo 
R, Oudin C, Mohty B, Bouabdallah R, et al. Antithymocyte globulin in 
reduced‑intensity conditioning regimen allows a high disease‑free sur‑
vival exempt of long‑term chronic graft‑versus‑host disease. Biol Blood 
Marrow Transplant. 2014;20:370–4.
 3. Dulery R, Mohty M, Duhamel A, Robin M, Beguin Y, Michallet M, Vig‑
ouroux S, Lioure B, Garnier A, El Cheikh J, et al. Antithymocyte globulin 
before allogeneic stem cell transplantation for progressive myelod‑
ysplastic syndrome: a study from the French Society of Bone Marrow 
Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 
2014;20:646–54.
 4. Kroger N, Zabelina T, Binder T, Ayuk F, Bacher U, Amtsfeld G, Lellek H, 
Schrum J, Erttmann R, Eiermann T, Zander A. HLA‑mismatched unrelated 
donors as an alternative graft source for allogeneic stem cell transplanta‑
tion after antithymocyte globulin‑containing conditioning regimen. Biol 
Blood Marrow Transplant. 2009;15:454–62.
 5. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Chen YH, Zhang XH, Lu 
DP. Treatment of acute leukemia with unmanipulated HLA‑mismatched/
haploidentical blood and bone marrow transplantation. Biol Blood Mar‑
row Transplant. 2009;15:257–65.
 6. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Chen YH, Wang JZ, Gao 
ZY, Zhang YC, et al. Haploidentical hematopoietic stem cell transplanta‑
tion without in vitro T‑cell depletion for the treatment of hematological 
malignancies. Bone Marrow Transplant. 2006;38:291–7.
 7. Finke J, Schmoor C, Lang H, Potthoff K, Bertz H. Matched and mis‑
matched allogeneic stem‑cell transplantation from unrelated donors 
using combined graft‑versus‑host disease prophylaxis including rabbit 
anti‑T lymphocyte globulin. J Clin Oncol. 2003;21:506–13.
 8. Mohty M. Mechanisms of action of antithymocyte globulin: T‑cell deple‑
tion and beyond. Leukemia. 2007;21:1387–94.
 9. Bacigalupo A. Antithymocyte globulin in the conditioning regimen: why 
not? Biol Blood Marrow Transplant. 2014;20:597–8.
 10. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, 
Volin L, Ruutu T, Heim DA, Schwerdtfeger R, et al. Standard graft‑
versus‑host disease prophylaxis with or without anti‑T‑cell globulin in 
haematopoietic cell transplantation from matched unrelated donors: 
a randomised, open‑label, multicentre phase 3 trial. Lancet Oncol. 
2009;10:855–64.
 11. Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Barto‑
lomeo P, Oneto R, Bruno B, Barbanti M, Sacchi N, et al. Antithymocyte 
globulin for graft‑versus‑host disease prophylaxis in transplants from 
unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti 
Midollo Osseo (GITMO). Blood. 2001;98:2942–7.
 12. Veys P, Wynn RF, Ahn KW, Samarasinghe S, He W, Bonney D, Craddock J, 
Cornish J, Davies SM, Dvorak CC, et al. Impact of immune modulation 
with in vivo T‑cell depletion and myleoablative total body irradiation 
conditioning on outcomes after unrelated donor transplantation for 
childhood acute lymphoblastic leukemia. Blood. 2012;119:6155–61.
 13. Bosch M, Khan FM, Storek J. Immune reconstitution after hematopoietic 
cell transplantation. Curr Opin Hematol. 2012;19:324–35.
 14. Na IK, Wittenbecher F, Dziubianau M, Herholz A, Mensen A, Kunkel D, Blau 
O, Blau I, Thiel E, Uharek L, et al. Rabbit antithymocyte globulin (thymo‑
globulin) impairs the thymic output of both conventional and regulatory 
CD4+ T cells after allogeneic hematopoietic stem cell transplantation in 
adult patients. Haematologica. 2013;98:23–30.
 15. Wang Y, Fu HX, Liu DH, Xu LP, Zhang XH, Chang YJ, Chen YH, Wang FR, 
Sun YQ, Tang FF, et al. Influence of two different doses of antithymo‑
cyte globulin in patients with standard‑risk disease following haploi‑
dentical transplantation: a randomized trial. Bone Marrow Transplant. 
2014;49:426–33.
 16. Bosch M, Dhadda M, Hoegh‑Petersen M, Liu Y, Hagel LM, Podgorny P, 
Ugarte‑Torres A, Khan FM, Luider J, Auer‑Grzesiak I, et al. Immune recon‑
stitution after anti‑thymocyte globulin‑conditioned hematopoietic cell 
transplantation. Cytotherapy. 2012;14:1258–75.
 17. Soiffer RJ, Lerademacher J, Ho V, Kan F, Artz A, Champlin RE, Devine S, 
Isola L, Lazarus HM, Marks DI, et al. Impact of immune modulation with 
anti‑T‑cell antibodies on the outcome of reduced‑intensity allogeneic 
hematopoietic stem cell transplantation for hematologic malignancies. 
Blood. 2011;117:6963–70.
 18. Schmidt‑Hieber M, Schwarck S, Stroux A, Ganepola S, Reinke P, Thiel E, 
Uharek L, Blau IW. Immune reconstitution and cytomegalovirus infection 
after allogeneic stem cell transplantation: the important impact of in vivo 
T cell depletion. Int J Hematol. 2010;91:877–85.
 19. Hillhouse EE, Lesage S. A comprehensive review of the phenotype and 
function of antigen‑specific immunoregulatory double negative T cells. J 
Autoimmun. 2013;40:58–65.
 20. Juvet SC, Zhang L. Double negative regulatory T cells in transplantation 
and autoimmunity: recent progress and future directions. J Mol Cell Biol. 
2012;4:48–58.
 21. Crispin JC, Tsokos GC. Human TCR‑alpha beta+ CD4− CD8− T cells can 
derive from CD8+ T cells and display an inflammatory effector pheno‑
type. J Immunol. 2009;183:4675–81.
 22. Martina MN, Noel S, Saxena A, Rabb H, Hamad AR. Double negative (DN) 
alphabeta T cells: misperception and overdue recognition. Immunol Cell 
Biol. 2015;93:305–10.
 23. D’Acquisto F, Crompton T. CD3+ CD4− CD8− (double negative) T 
cells: saviours or villains of the immune response? Biochem Pharmacol. 
2011;82:333–40.
 24. Cowley SC, Meierovics AI, Frelinger JA, Iwakura Y, Elkins KL. Lung CD4−
CD8− double‑negative T cells are prominent producers of IL‑17A and 
IFN‑gamma during primary respiratory murine infection with Francisella 
tularensis live vaccine strain. J Immunol. 2010;184:5791–801.
 25. Chakrabarti S, Mautner V, Osman H, Collingham KE, Fegan CD, Klapper 
PE, Moss PA, Milligan DW. Adenovirus infections following allogeneic 
stem cell transplantation: incidence and outcome in relation to graft 
manipulation, immunosuppression, and immune recovery. Blood. 
2002;100:1619–27.
 26. Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P, 
Einsele H, Cordonnier C, Acute, Chronic Leukemia Working P. Cause of 
death after allogeneic haematopoietic stem cell transplantation (HSCT) 
in early leukaemias: an EBMT analysis of lethal infectious complica‑
tions and changes over calendar time. Bone Marrow Transplant. 
2005;36:757–69.
 27. Wang LR, Dong LJ, Zhang MJ, Lu DP. The impact of human herpesvirus 6B 
reactivation on early complications following allogeneic hematopoietic 
stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:1031–7.
Page 10 of 10Liu et al. J Transl Med  (2015) 13:391 
 28. Willemsen L, Jol‑van der Zijde CM, Admiraal R, Putter H, Jansen‑
Hoogendijk AM, Ostaijen‑Ten Dam MM, Wijnen JT, Van Kesteren C, Waaijer 
JL, Lankester AC, et al. Impact of serotherapy on immune reconstitu‑
tion and survival outcomes after stem cell transplantations in children: 
thymoglobulin versus alemtuzumab. Biol Blood Marrow Transplant. 
2015;21:473–82.
 29. Lindemans CA, Chiesa R, Amrolia PJ, Rao K, Nikolajeva O, de Wildt A, 
Gerhardt CE, Gilmour KC, Bierings M, Veys P, Boelens JJ. Impact of thymo‑
globulin prior to pediatric unrelated umbilical cord blood transplantation 
on immune reconstitution and clinical outcome. Blood. 2014;123:126–32.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
